Wroclaw

• A study to learn more about how safe finerenone is, when it is taken for a longer time with standard treatment, in children and young adults … Recruiting
  2024-519830-22-00 5 2026-04-27 Heart failure due to systemic left ventricular systolic dysfunction
• Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting
  2025-522878-36-00 5 2026-04-20 Chronic Spontaneous Urticaria
• Dose-finding study of LAD603 in adults with alopecia areata Recruiting
  2025-523342-27-00 4 2026-04-10 Alopecia areata
• A study to learn if bimekizumab given in different ways is safe and moves similarly throughout the body over time in adults Recruiting
  2025-522782-30-00 3 2026-04-07 CCI
• A Phase II Study Evaluating the Efficacy and Safety of Inavolisib plus Ribociclib plus Fulvestrant Versus Placebo plus Ribociclib plus Fulve … Recruiting
  2025-523013-28-00 4 2026-04-07 Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced
• A Study in Pediatric Participants with Congenital Adrenal Hyperplasia Recruiting
  2024-519578-38-00 10 2026-03-30 Classic congenital adrenal hyperplasia
• A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have … Recruiting
  2025-521730-28-00 4 2026-03-30 Colorectal Cancer with Cancer Cachexia
• Visugromab in Cachexia International Trial Recruiting
  2025-523533-25-00 10 2026-03-26 Cancer-associated Cachexia
• A study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged 1 to less than 12 years with hemophilia A … Recruiting
  2025-521858-42-00 5 2026-03-16 Hemophilia
• A study to learn if DM199 drug is safe and whether it works better than placebo for treating acute ischemic stroke Recruiting
  2024-513911-28-00 10 2026-03-04 Acute Ischemic Stroke
• Essentiale® liquid once-daily Phase III study Recruiting
  2025-521678-32-00 5 2026-03-03 MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) / MAS
• A Study of the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy. Recruiting
  2025-522553-19-00 10 2026-02-25 Symptomatic genetic and familial dilated cardiomyopathy.
• A Phase III, randomized, controlled study of furazidin for bacterial vaginosis. Recruiting
  2024-515332-80-00 5 2026-02-23 Bacterial vaginosis
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety … Recruiting
  2024-520098-12-00 4 2026-02-16 Cutaneous Lupus Erythematosus
• Zasocitinib in Nonsegmental Vitiligo Recruiting
  2025-522309-40-00 4 2026-02-11 Non-segmental vitiligo
• A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRES … Recruiting
  2025-522170-36-00 5 2026-02-03 Diabetes Mellitus, Type 1
• A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific … Recruiting
  2025-522767-15-00 5 2026-01-27 Acute Myeloid Leukemia
• A Multi-Stage Study to Test a New Drug in Healthy Adult Volunteers, Then in Adults with Ulcerative Colitis Recruiting
  2025-522702-21-00 4 2026-01-26 Ulcerative Colitis is a type of inflammatory bowel disease, a chronic
• STOP-HAE: A Phase 3 Study of ADX-324 in HAE Recruiting
  2025-521352-38-00 5 2026-01-16 Hereditary Angioedema
• A study to learn how safe bimekizumab is and how well it works in adults with palmoplantar pustulosis Recruiting
  2024-520337-80-00 5 2026-01-07 Palmoplantar Pustulosis
• Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL. Recruiting
  2025-522052-13-00 10 2025-12-24 Framework for Optimizing, Refining, and Unifying Management of HSCT in
• Phase 2 Study of LAD191 in Adults With Hidradenitis Suppurativa Recruiting
  2025-521293-34-00 4 2025-12-09 Moderate-to-severe hidradenitis suppurativa
• A Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis who have not Responded to or … Recruiting
  2025-521034-28-00 4 2025-12-05 Moderate to Severe Rheumatoid Arthritis (RA)
• RVU120 Rollover Study Recruiting
  2025-521673-14-00 4 2025-12-03 Relapsed / Refractory Metastatic or Advanced Solid Tumors

Showing 73–96 of 838 trials